Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
6.86
USD
|
+0.15%
|
|
+1.18%
|
-38.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
187.2
|
-
|
-
|
Enterprise Value (EV)
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
187.2
|
187.2
|
187.2
|
P/E ratio
|
-10.1
x
|
-9.8
x
|
-6.57
x
|
-10.7
x
|
-18.7
x
|
13
x
|
12.4
x
|
3.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
2.95
x
|
2.83
x
|
1.98
x
|
EV / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
2.95
x
|
2.83
x
|
1.98
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
7.7
x
|
4.71
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-17.7
x
|
11.4
x
|
14
x
|
41
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-5.66%
|
8.76%
|
7.14%
|
2.44%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,896
|
25,810
|
26,007
|
26,261
|
26,994
|
27,324
|
-
|
-
|
Reference price
2 |
6.490
|
7.450
|
4.400
|
9.600
|
11.22
|
6.860
|
6.860
|
6.860
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.17
|
-
|
1.535
|
21.25
|
63.45
|
66.21
|
94.58
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
24.3
|
39.7
|
-
|
EBIT
1 |
-13.01
|
-17.88
|
-17.22
|
-22.59
|
-12.77
|
17.51
|
17.31
|
50.3
|
Operating Margin
|
-
|
-10,520.59%
|
-
|
-1,471.6%
|
-60.09%
|
27.6%
|
26.15%
|
53.18%
|
Earnings before Tax (EBT)
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-12.77
|
14.23
|
11.84
|
44.35
|
Net income
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-16.04
|
15.04
|
15.45
|
48.67
|
Net margin
|
-
|
-10,652.35%
|
-
|
-1,544.89%
|
-75.5%
|
23.71%
|
23.33%
|
51.46%
|
EPS
2 |
-0.6400
|
-0.7600
|
-0.6700
|
-0.9000
|
-0.6000
|
0.5267
|
0.5550
|
1.777
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.14
|
16.4
|
13.36
|
4.567
|
FCF margin
|
-
|
-
|
-
|
-
|
-80.67%
|
25.85%
|
20.18%
|
4.83%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
67.49%
|
33.66%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
109.02%
|
86.51%
|
9.38%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
1.535
|
1.677
|
3.325
|
6.515
|
9.735
|
25.38
|
11.22
|
12.3
|
14.56
|
16.26
|
15.82
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.4
|
3
|
5.5
|
15
|
7.3
|
EBIT
1 |
-4.207
|
-3.546
|
-5.009
|
-7.899
|
-6.135
|
-5.27
|
-4.666
|
-1.017
|
-1.818
|
13.74
|
-0.0982
|
1.099
|
2.776
|
4.958
|
1.82
|
Operating Margin
|
-
|
-
|
-
|
-
|
-399.67%
|
-314.25%
|
-140.33%
|
-15.61%
|
-18.67%
|
54.16%
|
-0.88%
|
8.94%
|
19.06%
|
30.5%
|
11.51%
|
Earnings before Tax (EBT)
1 |
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-1.818
|
12.84
|
-0.5712
|
0.1056
|
1.85
|
4.096
|
1.008
|
Net income
1 |
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-2.682
|
12.84
|
-0.667
|
0.5705
|
2.292
|
3.696
|
0.808
|
Net margin
|
-
|
-
|
-
|
-
|
-446.71%
|
-360.88%
|
-163.73%
|
-28.66%
|
-27.55%
|
50.59%
|
-5.95%
|
4.64%
|
15.74%
|
22.74%
|
5.11%
|
EPS
2 |
-0.1800
|
-0.1400
|
-0.1900
|
-0.3100
|
-0.2600
|
-0.2300
|
-0.2100
|
-0.0700
|
-0.1000
|
0.4100
|
-0.0250
|
0.0183
|
0.0817
|
0.1125
|
0.0875
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/12/22
|
8/12/22
|
11/11/22
|
3/29/23
|
5/11/23
|
8/3/23
|
11/6/23
|
3/21/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.1
|
16.4
|
13.4
|
4.57
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
3/30/21
|
2/28/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
6.86
USD Average target price
16.83
USD Spread / Average Target +145.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.86% | 187M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|